Original Article
Treatment Outcome and Relapse with Short-term
Oral Terbinafine 250 mg/day in Tinea Pedis
Iwao Takiuchi 1, Nobuaki Morishita 1, Taizo Hamaguchi 2,
1 Department of Dermatology, Showa University Fujigaoka Hospital
1-30 Fujigaoka, Aoba-ku, Yokohama, Kanagawa 227-8501, Japan
2 Department of Dermatology, Showa University, Northern Yokohama Hospital
35-1 Chigasakichuo, Tsuzuki-ku, Yokohama, Kanagawa 224-8503, Japan
Received: 22, February 2005. Accepted: 15, July 2005
Abstract
A total of 168 patients with tinea pedis, but without onychomycosis, were treated with 1 cycle of
mg/day for 1 week . KOH preparation for direct
microscopy was performed 4, 8 and 12 weeks after starting therapy to determine if testing was positive for tinea. Patients with no negative results on KOH examination or no evidence of obvious clinical improvement at 8 weeks, another cycle of the therapy was prescribed. The cure,
no cure, dropout, and discontinuation/unevaluable rates were 89.3%, 4.8%, 4.8% and 1.2%,
respectively. The number of cycles required for cure in the plantar type was 1 cycle in 65.9% and 2 cycles in 54.5% of cases; in the interdigital type, 1 cycle in 79.1% and 2 cycles in 20.9% of cases; and mixed type, 1cycle in 29.1% and 2 cycles in 60.9% cases. Among patients who were followed for at least 3 years after cure, the relapse rates were about 10% each year: 1 year, 11.3%; 2 years, 8.9%; and 3 years, 11.2%. The relapse rate of about 10% each year over a 3-year period suggests that reinfection may be likely.
Key words: oral terbinafine, treatment outcome, relapse rate, tinea pedis Introduction Patients and Methods
When treating tinea unguium using terbinafine
Over a 5-year period from January 1998 to
TBF , we have noticed that accompanying tinea
December 2002, 168 patients diagnosed with tinea
pedis is very easily treated, and recurrence is
pedis, based on clinical features and KOH
rare. In other countries, there have been many
examination, were treated with 1 cycle of oral
reports on the therapeutic effects of oral TBF
terbinafine TBF 1 cycle defined as 250 mg/day
on tinea pedis 1 4 . However, few reports of oral
for 1 week by the Department of Dermatology,
TBF for tinea pedis have been published in
Showa University Fujigaoka Hospital.
Japan because the use of TBF for tinea pedis
The patients in this study had no evidence of
of conventional form is not covered by health
onychomycosis. Of the 168 patients with tinea
We now report treatment outcome in these
interdigital-type and the remaining 24 had both
patients. In addition, among patients who were
plantar- and interdigital-type mixed-type .
followed for at least 3 years after cure, relapse
Follow-up examinations at 4, 8 and 12 weeks
after starting treatment included clinical and KOH examination. In general, regardless of the findings on KOH examination at 4 weeks, KOH
examination was again performed at 8 weeks to
1-30 Fujigaoka Aobaku Yokohama, 227-8501, Japan
determine if testing was positive for tinea. In
Department of Dermatology, Showa University Fujigaoka
patients with no negative results on KOH
examination or no evidence of obvious clinical
dropouts are excluded, the cure rate was
improvement at 8 weeks, another cycle of the
93.8% and the no cure rate was 5.0%. The
discontinued and unevaluable rates were both
In the present study, cure was defined as
follows: at either 8 or 12 weeks after the start of
Of the 150 patients cured of tinea pedis, 84
treatment, improved clinical symptoms were seen,
had the plantar type, 43 had the interdigital
and KOH examinations of scales collected from
type and 23 had the mixed type Table 2 .
several places and stratum corneum samples
harvested using a scalpel under a microscope
plantar type, 9 with the interdigital type and 14
did not show any fungal elements. Continued
with mixed type received two treatment cycles
negative results on KOH examination at 12 weeks,
even in the absence of marked improvement
Of the 8 patients without a cure, 1 patient
on clinical examination, was also defined as a
judged as having a cure 8 weeks after cycle 1
cure. Positive results on KOH examination at
of treatment had a relapse 1 month later. In
12 weeks or later after starting treatment,
each of the other patients, KOH examination
regardless of whether clinical examination showed
was positive at 4 to 8 weeks after cycle 2 of
treatment. Five of the patients had the interdigital
Treatment in these patients was changed.
type, 2 had both the interdigital and plantar
To evaluate relapse in patients judged as
cured, an attempt was made to schedule follow-
There were 115 patients who were followed
up evaluations including KOH examination.
for at least 3 years after completing treatment.
The presence or absence of a relapse in the
Figure 1 depicts the changes in relapse rates
patients who achieved a cure was evaluated by
from 1 to 3 years in these patients. At 1 year,
a clinic visit or contacting the patient by phone
or e-mail each year from late August to early
relapse, 13 11.3% had a relapse, and in one
September. Eighty two of the patients were
0.9% , the status was unknown. At 2 years,
evaluated through contact by phone or e-mail;
the other 68 patients were evaluated at a clinic
relapse, 9 8.9% had a relapse, and the status
was unknown in 3 3.0% . At 3 years, 74 of 89 patients
had a relapse, and in 5 5.6% , the status was
The results of the 168 patients treated with
oral TBF are summarized in Table 1. Treatment
Of the 115 patients followed for at least 3
years, there were 58 cases of plantar type, 16
cases of interdigital type and 21 cases of mixed
started treatment but did not return to clinic
type. The number of relapses over 3 years was
for follow-up. Treatment was discontinued or
15 in the plantar type, 15 in the interdigital
Discussion
Table 1. Treatment outcome of tinea pedis with intermittent
In addition to clinical examination and KOH
examination by direct microscopy, culture findings have been regarded as essential to evaluate a
cure . However, not all lesions can be cultured
or examined with KOH, so complete evaluation
of microbiological cure is nearly impossible. A
better clinical indicator is whether the patient
again develops tinea pedis the following summer 1 .
Table 2. Number of cures for each tinea pedis clinical type
Table 3. Number of cycles of treatment until cure
In the present study, we decided to use a
the data reported in these 2-week continuous
marked improvement on clinical examination
treatment studies. However, in our treatment
and findings on KOH examination as evaluation
regimen, an additional cycle of therapy was
criteria for cure . Even if KOH examination was
prescribed only when clinical or KOH examination
positive, mycological culture of skin materials
after 8 weeks showed no obvious improvement.
was not performed from all patients as a basis
As shown in Table 3, among patients with a
for initial diagnosis. We cannot deny that there
cure, 29 with the plantar type, 9 with the
was a slightly insufficient basis for the initial
interdigital type and 14 with the mixed type
received two cycles of treatment. However, in 7
The cure no cure and dropout rates in our
cases with the plantar type, 3 of the interdigital
study were 89.3%, 4.8%, and 4.8%, respectively
type and 4 of the mixed type, KOH examination
Table 1 . Of the patients who did not return
at 8 weeks after the starting cycle corresponding
for follow-up and were considered dropouts,
to the scheduled day for starting cycle 2 was
13 patients were judged to be cured based
negative, and clinical examination also showed
on telephone interviews or examination 2 years
improvement. Nevertheless, these patients requested
or later when they visited our clinic for
that another cycle of treatment be prescribed.
another disorder. Therefore, most of the 8
If all these patients were judged as being
dropout patients, in fact, likely were cured of
cured after 1 cycle, two cycles of treatment
tinea pedis. If we exclude the 8 dropout
were required for a cure in 22 patients with
patients, the cure rate was 93.8% and the
the plantar type, 6 patients with interdigital
type and 10 patients with mixed type. The
discontinued in 1 patient because of abdominal
majority of patients responded after 1 cycle of
pain. In the unevaluable patient, T. rubrum was
treatment. Surprisingly, fungal elements of
cultured at the initial evaluation, but Candida
dermatophytes were detected in plantar callosity
was found at the same site 2 months later.
of six patients, but KOH examination was
Because of the microbial substitution, rating this
negative after 1 cycle of treatment. In 1 patient,
patient as cured may have been appropriate,
there was a relapse during the following year;
but clinical examination showed no change, so
there were no relapses in the other patients.
only the interdigital type. In another patient
Barnetson et al. 2 compared 1 week of oral TBF
with both the plantar and interdigital type,
250 mg/day with 4 weeks of topical clotrimazole.
there was recurrence only on the interdigital
region. This suggests that interdigital tinea
therapy in both groups were approximately
pedis may be more refractory to treatment than
72% and not significantly different. After 16
plantar tinea pedis. Furthermore, over a 3-year
weeks with clotrimazole cream there was still
period, the relapse rate for the interdigital type
no significant difference, but the cure rate was
29.8% was higher than for the plantar type
only 54.9% in the TBF group. In our study, if
15.2% . Of the 8 patients with no cure 3
we assume treatment was completed after 1
patients stopped coming to the clinic, so their
week of therapy, the cure rate for both plantar
clinical course is unknown. One patient continued
type and interdigital type tinea pedis was 66.2%
topical therapy but had repeated infections. In
114 of 172 cases . This is not considerably
4 patients, continuous treatment with TBF 125
different from the rate reported by Barnetson
mg/day was prescribed. Two patients had a
et al. 2 In another study of oral TBF in tinea
cure with 1 month of treatment, but the other
pedis, Hay et al. 3 compared 2 weeks of oral
2 patients had no response to therapy. With
TBF 250 mg/day with 4 weeks of oral itraconazole
continuous oral TBF 250 mg/day , a cure was
100 mg/day . After 16 weeks, the cure rate
judged after 5 weeks and after 8 weeks.
with TBF was 78%. Keyser et al. 4 treated 184
between the patient and physician regarding a
weeks and reported a clinical cure rate of
relapse; preference was given to the opinion of
94.1% and microbiological cure rate of 88.6%
the physician. Although patients who had a
after 2 months. Using a similar regimen, White
relapse often came back to the clinic, there
et al. 5 treated patients with tinea pedis and
were relatively few who returned every year
tinea manuum and reported microbiological
merely to show whether or not they had has a
cure rates of 64% after 4 weeks and 86% after
relapse. Therefore, we had to evaluate these
8 weeks. The results in our study are similar to
patients by phone or e-mail interview. Of thoses
㪈㩷㫐㪼㪸㫉㩷㩿㫅㪔㪈㪈㪌㪀
㪉㩷㫐㪼㪸㫉㫊㩷㩿㫅㪔㪈㪇㪈㪀
㪊㩷㫐㪼㪸㫉㫊㩷㩿㫅㪔㪏㪐㪀
Fig. 1. Relapse rates over the 3-year period after cure
The figure depicts results in 115 patients who were followed for at least 3 years after cure.
evaluated by phone or e-mail, about 90% said
relatively low compared to topical therapy.
they had no relapse and 10% said they had
Although health insurance coverage may be a
had a relapse. However, of the patients evaluated
problem, the fact that many patients only
at a clinic visit, about one half had no
require 2 or 3 clinic visits means a savings in
costs. This, combined with the very low relapse
The number of patients lost to follow-up
rates, makes oral TBF, in our opinion, the best
increased each year and reached more than
treatment of choice for many patients with
half the cases by 4 years after treatment. This
tinea pedis. However, misdiagnosis may be a
would not be statistically meaningful, so we
potential problem. Accurate diagnosis at the
decided to evaluate the presence or absence of
initial evaluation should preferably include
relapse in patients followed for 3 years or
fungal cultures, or at a minimum, the presence
longer, which included at least 100 patients.
of fungal elements on direct KOH examination.
Although the number lost to follow-up increased
The issue of recurrence versus reinfection
each year, we found that over a 3-year period,
must always be considered in patients with
approximately 85% of patients had no relapse
relapse 1. Our findings of an approximately 10%
and approximately 10% of patients had a relapse
relapse rate each year over a 3-year period suggest
that reinfection is more likely than recurrence.
Topical therapy has been regarded as relatively
References
ineffective for hyperkeratotic tinea pedis 6 , but a fungus negative conversion rate of 80.6% for
1 Kagawa S: Prognosis in tinea pedis. Jpn J Med
lesions with some degree of keratinization has
Mycol 9: 109 114, 1968.
also been reported 7 . This is not substantially
different from our results, but few reports have
Brookman S, Cowen P, Ellis D and Williams T:
addressed the issue of relapse after topical
Comparison of one week of oral terbinafine
250 mg/day with four weeks of treatment with
therapy. In 380 patients with tinea pedis who
clotrimazole 1% cream in interdigital tinea
pedis. Brit J Dermatol 139: 675 678, 1998.
Nishimoto 8 reported a cure in only 27 cases.
3 Hay RJ, McGregor JM, Wuite J, Ryatt KS,
In that study, the principal clinical problem was
Ziegler C, Clayton YM: A comparison of 2
that despite treatment for several to over 10
weeks of terbinafine 250 mg/day with 4 weeks
years, many patients still had recurrent relapses.
of itraconazole 100 mg/day in plantar-type tinea
In addition, several studies following patients
pedis. Brit J Dermatol 132: 604 608, 1995.
after cure for at least 1 year found relapse
4 Keyser P De, Backer M De, Massart DL,
rates of approximately 50% at 1 year and
Westelinck KJ: Two-week oral treatment of tinea
thereafter 9 11 . In our study, the relapse rates of
pedis, comparing terbinafine 250 mg/day with
approximately 10% each year with oral TBF are
multicentre study. Brit J Dermatol 130 Suppl.
9 Elewski BE, Bergstresser PR, Hanifin J, Lesher
5 White JE, Perkins PJ and Evans EGV: Successful
J, Savin R, Shupack J, Stiller M, Tschen E,
2-week treatment with terbinafine Lamisil
for moccasin tinea pedis and tinea manuum.
outcome of patients with interdigital tinea
Brit J Dermatol, 125: 260 262, 1991.
pedis treated with terbinafine or clotrimazole.
6 Takahashi S: Topical therapy in tinea pedis-
J Am Acad Dermatol 32: 290 292, 1995.
Indications for topical therapy and clinical
10 Watanabe S, Takahashi H: Clinical evaluation of
significance of steroid-containing antifungal
preparations. Jpn J Med Mycol 9: 94 98, 1968.
pedis - Usefulness and relapse rates. The Nishi-
7 Bifonazole Research Group: Evaluation of
nihon Journal of Dermatology 59: 293 298,
efficacy and safety of lanoconazole cream in
hyperkeratotic tinea pedis. The Nishinihon
11 Naka W: Prevention of recurrent tinea Effective-
Journal of Dermatology 55: 961 971, 1993.
ness of long-term topical application of anti-
8 Nishimoto K: Problems in the treatment of tinea
fungal drugs after initial treatment. Medical
pedis patients. Jpn J Med Mycol 35: 335 339,
Tribune 11: 18 19, December 1997.
Patient Name______________________________________Date______________________________ Medical Physician’s Name & Phone___________________________________________________________ Please answer the following health questions as completely as possible (circle YES or NO) 1. Do you consider yourself to be in good health? 2. Are you now or have you been under a physicians care within the
Step Therapy Criteria Drug Name Step Therapy Criteria Step 1- PATIENT NEEDS TO HAVE A DOCUMENTED TRIAL OF ANY TWO OF THE FOLLOWING DRUGS, 1 DRUG FROM EACH CLASS, IN THE PREVIOUS 120 DAYS BEFORE MOVING TO STEP 2: ACE-Inhibitor (including combinations with HCTZ) Benazepril Hcl, Benazepril Hcl/Hydrochlorothiazide, Captopril, Captopril /Hydrochlorothiazide, Enalapril Maleate, Enalapri